Healio

Tremfya nabs FDA approval for active ulcerative colitis, chasing competitor Skyrizi

Please provide your email address to receive an email when new articles are posted on . The FDA has approved Johnson & Johnson’s Tremfya, a dual acting interleukin-23 inhibitor, for the treatment of ...
Seeking Alpha

Johnson & Johnson's Tremfya: A Potential Blockbuster Drug

Tremfya was approved by the FDA for the treatment of adults suffering from moderate to severe plaque psoriasis. With the FDA’s decision, Tremfya becomes the only approved biologic therapy that only ...
Nasdaq

TREMFYA® (guselkumab) demonstrates impressive results across biologic-naïve and biologic-refractory patients in Crohn's disease and ulcerative colitis

TREMFYA® is the only IL-23 inhibitor to demonstrate superiority to ustekinumab in the overall population of patients with Crohn's disease, inclusive of those who are biologic-naïve and ...
Seeking Alpha

TREMFYA® (guselkumab) achieves U.S. approval for subcutaneous induction in adults with ulcerative colitis, now the first and only IL-23 inhibitor with a fully subcutaneous regimen

TREMFYA ® offers the flexibility of self-administration from the start of treatment, building on the prior approval of subcutaneous induction in Crohn's disease TREMFYA ® achieved significant rates of ...
Healthline

Tremfya Interactions: Alcohol, Medications, and Others

Tremfya (guselkumab) has potential interactions with certain other medications, such as abatacept (Orencia) and paroxetine (Brisdelle, Paxil). Using Tremfya may also affect how your body responds to ...